Actionable Information to Aid in Patient Care
Completion of the Human Genome Project in 2003 has ushered in the era of genomic medicine, and with it, the potential of more individualized patient care. The application of advanced genomic technologies to clinical medicine provides detailed information about an individual’s disease at the molecular and cellular levels.
Corus™ CAD is a gene expression test that provides an actionable, current-state assessment of the likelihood of obstructive* coronary artery disease (CAD), rather than a prediction of lifetime risk. Combining genomic test results with traditional non-invasive assessments provides physicians with a more complete picture of their patient’s disease state.
More Corus CAD Benefits.
* Obstructive CAD is defined as at least one atherosclerotic plaque causing ≥50% luminal diameter stenosis in a major coronary artery (≥1.5 mm lumen diameter) as determined by invasive quantitative coronary angiography (QCA).
